For a better user experience please update your browser or use Chrome or Firefox browser.
Utilities
Publication detail
HomeOpinion on Benzyl Salicylate (CAS No. 118-58-1, EC No. 204-262-9)
Publication metadata
In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of Benzyl Salicylate, does the SCCS consider Benzyl Salicylate safe when used up to the maximum concentrations provided in the dossier submission by the Benzyl Salicylate Consortium? Based on the assessment of data provided and taking under consideration the concerns related to potential endocrine disrupting properties, the SCCS considers Benzyl Salicylate safe when used up to the maximum concentrations as provided in Table 1 of this Opinion. (2) Alternatively, what is according to the SCCS the maximum concentration considered safe for use of Benzyl Salicylate in cosmetic products? / (3) Does the SCCS have any further scientific concerns with regard to the use of Benzyl Salicylate in cosmetic products? The available data on Benzyl Salicylate provide some indications for an endocrine mode of action, but there is no evidence to suggest that this results in endocrine effects. The SCCS mandates do not address environmental aspects. Therefore, this assessment did not cover the safety of Benzyl Salicylate for the environment.
- Published:
- Themes: Pharmaceutical and cosmetics industry , Consumers' health
- Subject: chemical product , chemicals legislation , consumer protection , cosmetic product , endocrine disruptor , environmental impact , health risk , research , safety standard , scientific report , toxic substance
|
PDF
|
|||
| ISSN 1831-4767 | ISBN 978-92-68-19384-6 | DOI 10.2875/160899 | Catalogue number EW-AQ-24-001-EN-N |
- Released on EU publications website:
Document viewer
Note:
The publication cannot be displayed in the document viewer. Open web version
You may access it from: Download and languages